JAK-STAT inhibitors such as baricitinib, fedratinib, and ruxolitinib are approved drugs for rheumatoid arthritis treatment and currently used for the treatment of COVID-19 patients through the suppression of elevated cytokine levels (Stebbing et al., 2020). The gene discussed is SOAT1; the disease is COVID-19.